1. Additional Drug Resistance of Multidrug-Resistant Tuberculosis in Patients in 9 Countries.
- Author
-
Kurbatova, Ekaterina V., Dalton, Tracy, Ershova, Julia, Tupasi, Thelma, Caoili, Janice Campos, Van Der Walt, Martie, Kvasnovsky, Charlotte, Yagui, Martin, Bayona, Jaime, Contreras, Carmen, Leimane, Vaira, Via, Laura E., Kim, HeeJin, Akksilp, Somsak, Kazennyy, Boris Y., Volchenkov, Grigory V., Jou, Ruwen, Kliiman, Kai, Demikhova, Olga V., and Cegielski, J. Peter
- Subjects
DRUG resistance ,FLUOROQUINOLONES ,MULTIDRUG-resistant tuberculosis ,PHARMACOLOGY ,MULTIDRUG resistance - Abstract
Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no resistance to fluoroquinolones and second-line injectable drugs and thus would qualify as candidates for the 9-month regimen; 302 (24.1%) patients with resistance to a fluoroquinolone or second-line injectable drug would qualify as candidates for a bedaquiline-containing regimen in accordance with published guidelines. Among candidates for the 9-month regimen, standardized drug-susceptibility tests demonstrated susceptibility to a median of 5 (interquartile range 5-6) drugs. Among candidates for bedaquiline, drug-susceptibility tests demonstrated susceptibility to a median of 3 (interquartile range 2-4) drugs; 26% retained susceptibility to ≤2 drugs. These data may assist national TB programs in planning to implement new drugs and drug regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF